CanSino Biologics, Inc. Class H (CJH) AI Stock Analysis

1 Followers

CanSino Biologics, Inc. Class H

(Frankfurt:CJH)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue reboundThe strong TTM revenue rebound and renewed growth in 2024–2025 indicate recovering commercial demand and improved business traction. If this momentum persists, higher sales can support greater manufacturing utilization, broaden market reach, and provide a stronger base for future profitability.

Negative Factors

Negative free cash flowNegative free cash flow means reported operating activity is not yet covering investment needs, limiting the cash available for strategic initiatives and balance-sheet strengthening. The persistence of negative free cash flow across prior years raises concern that revenue recovery may require continuing financial support.

CanSino Biologics, Inc. Class H (CJH) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 8.51B
Dividend Yield: ―
Average Volume (3M): 651
Price to Earnings (P/E): 575.1
Beta (1Y): 1.16
Revenue Growth: 30.09%
EPS Growth: ―
Country: Germany
Employees: 1,134
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CanSino Biologics, Inc. Class H Business Overview & Revenue Model

Company Description

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus...

CanSino Biologics, Inc. Class H Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:CJH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:3692	75Outperform	HKD 193.93B	25.15	18.26%	1.52%	24.97%	43.23%
HK:9989	56Neutral	HKD 14.60B	71.29	1.58%	4.11%	-1.32%	-50.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:2627	49Neutral	HKD 11.54B	-37.74	-101.49%	―	―	―
HK:0013	45Neutral	HKD 18.07B	141.65	1.43%	―	-8.55%	-96.20%
HK:2575	40Underperform	HKD 4.00B	-17.00	-15.68%	―	237.19%	61.28%

* Healthcare Sector Average

Performance Comparison

DE:CJH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:CJH	CanSino Biologics, Inc. Class H	2.90	-2.08	-41.77%
HK:0013	HUTCHMED (China) Limited	20.56	-3.50	-14.55%
HK:9989	Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H	4.04	-1.22	-23.22%
HK:3692	Hansoh Pharmaceutical Group Company Limited	31.94	-3.58	-10.09%
HK:2627	Ab&B Bio-Tech CO., LTD. JS Class H	29.32	-11.08	-27.43%
HK:2575	Xuanzhu Biopharmaceutical Co., Ltd. Class H	8.11	-57.39	-87.63%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

CanSino Biologics, Inc. Class H AI Stock Analysis